The primary objective of this study is to determine if Gallium-68 labeled DOTA-TOC will result in the delineation of more lesions in patients with somatostatin receptor positive malignancies than with conventional imaging.
Known or suspected somatostatin receptor positive tumor such as carcinoid;neuroendocrine tumor; neuroblastoma; pheochromocytoma. Supporting evidence may include MRI, CT, biochemical markers, and or pathology report.
Karnofsky performance status of> 50 (or ECOG/WHO equivalent).
Not pregnant. A negative serum pregnancy test is required for all female subjects with child-bearing potential.
Ability to understand a written informed consent document, and the willingness to sign it
You CAN'T join if...
Hepatic enzymes 5 times greater than the upper limits of normal, serum creatinine> 3.0 mg/dL (270 uM/L)
Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET/CT scanner due to BMI
Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,etc.)
Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
Recognized concurrent active infection
Previous systemic or radiation treatment for another cancer of any type within the last 2 months
Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments.
UCSF Imaging Center at China Basinaccepting new patients San Francisco, California, 94107, United States